Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ADTX 
Aditxt Inc. (ADTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/06/2025: ADTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -31.78% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.16M USD | Price to earnings Ratio - | 1Y Target Price 61 |
Price to earnings Ratio - | 1Y Target Price 61 | ||
Volume (30-day avg) 129028240 | Beta 1.11 | 52 Weeks Range 4.11 - 34200.00 | Updated Date 04/3/2025 |
52 Weeks Range 4.11 - 34200.00 | Updated Date 04/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -21763.66 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -68588.25% |
Management Effectiveness
Return on Assets (TTM) -99.05% | Return on Equity (TTM) -35568.57% |
Valuation
Trailing PE - | Forward PE 0.37 | Enterprise Value 14937254 | Price to Sales(TTM) 24.31 |
Enterprise Value 14937254 | Price to Sales(TTM) 24.31 | ||
Enterprise Value to Revenue 70.42 | Enterprise Value to EBITDA 0.02 | Shares Outstanding 1031100 | Shares Floating 56935 |
Shares Outstanding 1031100 | Shares Floating 56935 | ||
Percent Insiders - | Percent Institutions 0.03 |
Analyst Ratings
Rating 4 | Target Price 61 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aditxt Inc.
Company Overview
History and Background
Aditxt, Inc. is a biotechnology company focusing on technologies designed to improve the health of the immune system, protect against disease, and extend lifespan. Founded in 2017, it has pursued various acquisitions and developments in immune monitoring and reprogramming.
Core Business Areas
- AditxtScore: An immune monitoring test that can help detect the presence of antibodies associated with specific autoimmune diseases.
- Apoptots: A therapeutic approach that aims to reprogram the immune system to treat or prevent autoimmune diseases and allergies.
Leadership and Structure
The leadership team includes Amro Albanna (CEO) and Dr. Shahrokh Abbasian (Chief Scientific Officer). The organizational structure is typical of a small biotechnology company.
Top Products and Market Share
Key Offerings
- AditxtScore: A diagnostic test for immune system health. Market share is still developing. Competitors include companies offering similar diagnostic tests, such as those from LabCorp and Quest Diagnostics.
- AditxtReprogramming: A therapeutic program to reprogram the immune system to treat allergies and other autoimmune diseases. No market share or revenue yet, this treatment is still under research. Competitors are various other companies exploring immune therapies, such as Novartis and Regeneron.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and innovative, with constant advancements in diagnostics and therapeutics. Focus areas are immune monitoring and reprogramming.
Positioning
Aditxt is a small player attempting to establish itself in the biotechnology market with novel approaches to immune health and disease treatment. Competitive advantages are their novel therapeutic platform.
Total Addressable Market (TAM)
The TAM for immune monitoring and reprogramming is potentially in the billions of dollars. Aditxt is positioned to capture a segment of this market through their innovative platform.
Upturn SWOT Analysis
Strengths
- Novel therapeutic platform (Apoptots)
- Focus on immune system health
- Experienced leadership team
Weaknesses
- Limited financial resources
- Early stage of product development
- Low brand recognition
Opportunities
- Partnerships with larger pharmaceutical companies
- Expanding applications of Apoptots technology
- Growing market for immune monitoring and reprogramming
Threats
- Competition from established biotechnology companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- LabCorp (LH)
- Quest Diagnostics (DGX)
- Novartis (NVS)
- Regeneron (REGN)
Competitive Landscape
Aditxt faces strong competition from larger, more established companies in the biotechnology and diagnostics space. Their success depends on their ability to innovate and secure partnerships.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been limited to acquisitions and development of their therapeutic platform. No specific growth numbers available.
Future Projections: Future growth is highly dependent on the successful development and commercialization of their products.
Recent Initiatives: Recent initiatives focus on clinical trials for Apoptots and commercialization of AditxtScore.
Summary
Aditxt is a small biotechnology company with innovative technologies but faces significant challenges. Its strength lies in its novel therapeutic platform, but its weaknesses include limited financial resources and a competitive landscape. Future success depends on positive clinical trial outcomes and strategic partnerships. Their market share is minimal relative to the large players in its markets.
Similar Companies
DGX
Quest Diagnostics Incorporated
DGX
Quest Diagnostics Incorporated
LH
Laboratory Corporation of America Holdings
LH
Laboratory Corporation of America Holdings
NVS
Novartis AG ADR
NVS
Novartis AG ADR
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered investment advice. The biotechnology industry is subject to rapid change, and the information provided may not be current.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aditxt Inc.
Exchange NASDAQ | Headquaters Richmond, VA, United States | ||
IPO Launch date 2020-06-30 | Co-Founder, Chairman & CEO Mr. Amro A. Albanna | ||
Sector Healthcare | Industry Biotechnology | Full time employees 47 | Website https://www.aditxt.com |
Full time employees 47 | Website https://www.aditxt.com | ||
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.